Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertension.
"MK-421" a new oral converting enzyme inhibitor was administered to 16 hypertensive patients in doses ranging between 2.5-40 mg once daily for periods of 6-18 weeks. The blood pressure, plasma renin activity, plasma angiotensin II, aldosterone and angiotensin converting enzyme activity were assessed before and during treatment. Blood pressure normalized in 11 patients and decreased significantly in the remaining 5, without significant changes in heart rate or orthostatic hypotension. At 24 hrs after the first effective dose, plasma renin activity remained elevated to 228% whereas plasma angiotensin II was suppressed to 58%, aldosterone was suppressed to 40% and angiotensin converting enzyme activity was suppressed to 16% of the baseline. Magnitude of blood pressure decrement achieved with the maximal dose did not correlate with baseline plasma renin activity levels. No side-effects were noted during the 6-18 week period of observation.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004151:Dipeptides / Q000627:therapeutic use*; D004656:Enalapril; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000378:metabolism; D012083:Renin / Q000097:blood; D012964:Sodium / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004151:Dipeptides; D004656:Enalapril; D012964:Sodium; D012083:Renin; D011188:Potassium